IFN-γ and CD38 in Hyperprogressive Cancer Development.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) have improved cancer patient survival but face limitations due to low response rates and atypical responses.
• Hyperprogressive disease (HPD), a paradoxical acceleration of tumor growth post-ICI treatment, presents a significant clinical challenge.
• The underlying mechanisms of HPD remain unclear and debated, necessitating further investigation into contributing factors.

Purpose of the Study:

• To explore the potential involvement of IFN-γ and CD38 in the pathogenesis of hyperprogressive disease (HPD) following immune checkpoint inhibitor (ICI) therapy.
• To propose novel hypotheses regarding the mechanisms by which IFN-γ and CD38 may contribute to HPD.
• To highlight key pathways and cellular processes potentially linking these factors to HPD.

Main Methods:

• This review synthesizes existing literature on immune checkpoint inhibitors, hyperprogressive disease, IFN-γ, and CD38.
• It analyzes the known functions and associations of IFN-γ and CD38 with cancer immunity and ICI resistance.
• The review proposes hypothetical mechanisms for HPD involvement based on current immunological and molecular understanding.

Main Results:

• Interferon-gamma (IFN-γ) may promote HPD through inflammasome activation, indoleamine 2,3-dioxygenase 1 (IDO1) activity, and activation-induced cell death (AICD) in T cells.
• CD38 might contribute to HPD by activating adenosine receptors, influencing hypoxia pathways, and mediating AICD-dependent T-cell depletion.
• Both IFN-γ and CD38 are implicated in resistance to ICI therapy, suggesting a potential link to HPD.

Conclusions:

• IFN-γ activation of the inflammasome pathway, IDO1, and AICD may drive HPD.
• CD38's role in HPD could involve adenosine receptor and hypoxia pathway activation, alongside AICD-driven T-cell loss.
• Further research into IFN-γ and CD38 is crucial for understanding and potentially mitigating HPD in cancer patients treated with ICIs.